'The spirit of Dr Paul Janssen is still guiding us,' says J&J's head of public health

10 August 2017

As the recent G20 Summit kicked off amid unprecedented civil unrest, advocates and lobbyists of every stripe descended on Hamburg in an effort to push their agenda.

For Jaak Peeters, head of global public health at Johnson & Johnson (NYSE: JNJ), that means persuading world leaders to invest more in projects to check some of the world’s most challenging and injurious diseases.

“We need support from government and political leaders,” Mr Peeters says. “When you consider the UN sustainable development goals up to 2030, which are extremely ambitious, we can only achieve these if we form powerful public-private partnerships.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK